title: PTH increases jaw mineral density in a rabbit model of osteoporosis.
abstract: Intermittent parathyroid hormone (PTH) administration has been shown to be a promising therapy for systemic bone loss. Accordingly, we hypothesized that PTH could have positive results in treating oral complications of osteoporosis. Hence, we evaluated both mandibular bone loss and its response to PTH in a rabbit model of osteoporosis induced by ovariectomy and glucocorticoid administration. There was a significant and marked decrease in bone mineral density (BMD), bone mineral content (BMC), and calcium content in ash from the osteoporotic peri-alveolar region, which influenced global jaw loss. Remarkably, PTH (1-34) administration to osteoporotic rabbits almost completely reversed BMD, BMC, and calcium content fall in the peri-alveolar region, subsequently reducing global mandibular bone loss. Thus, although the peri-alveolar region is particularly susceptible to osteoporosis, it also responds well to intermittent PTH. Therefore, these results suggest that PTH might represent a valid therapy for improving the osseointegration of dental implants in persons with osteoporosis.
authors.affiliation: Bone and Joint Research Unit, Service of Rheumatology, Fundación Jiménez Díaz, Universidad Autónoma, Av. Reyes Católicos 2, 28040-Madrid, Spain.
authors.forename: M
authors.initials: M
authors.lastname: Bellido
authors.forename: L
authors.initials: L
authors.lastname: Lugo
authors.forename: S
authors.initials: S
authors.lastname: Castañeda
authors.forename: J A
authors.initials: JA
authors.lastname: Roman-Blas
authors.forename: J A
authors.initials: JA
authors.lastname: Rufián-Henares
authors.forename: M
authors.initials: M
authors.lastname: Navarro-Alarcón
authors.forename: R
authors.initials: R
authors.lastname: Largo
authors.forename: G
authors.initials: G
authors.lastname: Herrero-Beaumont
mesh_terms: D000539:Alveolar Process / Q000378:metabolism / Q000473:pathology; D000818:Animals; D015519:Bone Density / Q000187:drug effects*; D050071:Bone Density Conservation Agents / Q000494:pharmacology / Q000627:therapeutic use*; D004195:Disease Models, Animal; D005260:Female; D005938:Glucocorticoids; D008334:Mandible / Q000378:metabolism / Q000473:pathology*; D008776:Methylprednisolone Hemisuccinate; D010024:Osteoporosis / Q000139:chemically induced / Q000188:drug therapy* / Q000378:metabolism; D010052:Ovariectomy; D010281:Parathyroid Hormone / Q000494:pharmacology / Q000627:therapeutic use*; D011817:Rabbits
chemical_list: D050071:Bone Density Conservation Agents; D005938:Glucocorticoids; D010281:Parathyroid Hormone; D008776:Methylprednisolone Hemisuccinate